Saturday 17 October 2026 Export MDRX’s income statement to Excel — free account

Veradigm Inc.

MDRX Healthcare Health Information Services

5.00 0.00 0.00%

Follow MDRX

Alert me

Market cap: $654.5M
P/E: 0.0×
Fwd P/E: −11.4×
Dividend yield: —
F-score: 1/9
Altman Z: 1.65
Beneish M: −3.57
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 3.88%

Capital & Financial Ratios $m

Market Cap 654.47

Revenue 588.02

Net Income (20.04)

Free Cash Flow 84.56

Net Debt (247.50)

Current Ratio 2.95

Debt/Equity 0.20

P/E ratio 0.00

Fwd P/E (11.40)

P/S ratio 0.95

P/B ratio 0.55

Past 5Y EPS Growth —

This Y EPS Growth 1.52%

Next Y EPS Growth (5.49%)

Next Y revenue growth (1.63%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 20.95%

10-year low 10-year high

P/B against its own 10 years 14.23%

10-year low 10-year high

EV/Sales against its own 10 years 14.57%

10-year low 10-year high

EV/FCF against its own 10 years 21.07%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2021	2022	2023	2024
Cash	135	448	447	294
Receivables	120	119	111	108
Inventory	—	—	—	—
Other	65	57	87	91
	649	680	699	546

	2021	2022	2023	2024
Payables	2	31	21	31
ST’ Debt	20	—	205	155
Other	511	—	12	15
	488	230	446	422

Compound Annual Growth %

	10y	5y	3y
Sales	(8.06%)	(18.30%)	0.97%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(4.58%)	(8.95%)	(16.08%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	—	—	—	—	594
’23	—	—	—	—	626
’22	143	151	152	143	588
’21	134	141	145	158	577
’20	381	369	366	—	556
’19	432	444	444	312	1,633

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	—	—	—	—	(20)
’23	—	—	—	—	100
’22	69	(2)	28	21	117
’21	5	(201)	56	64	(77)
’20	(4)	23	53	(176)	(104)
’19	6	(8)	36	12	46

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	—	—	—	—	(50)
’23	—	—	—	—	70
’22	59	(12)	20	17	85
’21	(4)	(210)	45	50	(118)
’20	(33)	(4)	30	(142)	(149)
’19	(28)	(39)	1	(8)	(74)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	—	—	—	—	(2.70)
’23	—	—	—	—	0.39
’22	0.17	(0.54)	0.12	(0.51)	(0.77)
’21	0.06	0.15	0.12	0.68	0.97
’20	(0.13)	(0.05)	0.00	4.82	4.40
’19	(0.04)	(0.90)	(0.03)	(0.12)	(1.10)

Fiscal quarters ending in the months shown.

Group	Line	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e
Price, $
Price, $	Low	—	9.80	10.24	8.54	8.75	4.56	13.05	13.59	9.34	5.01	Analyst estimates 2025–2027 Powerpack
	High	—	15.17	15.20	16.13	12.40	14.91	19.01	23.25	19.77	11.80
People
People	Employees	—	7,500	8,900	9,500	9,600	8,400	8,000	2,450	—	2,300
	Revenue/emp, $m	—	0.18	0.17	0.17	0.17	0.07	0.07	0.24	0.00	0.26
Income, $m
Income, $m	Revenue	—	1,386	1,498	1,618	1,633	556	577	588	626	594
	Gross margin, %	—	43.38	42.25	38.41	37.38	47.51	48.91	52.45	54.56	50.85
	EBT	—	32	(190)	(62)	(282)	(13)	158	(63)	60	(215)
	EBT margin, %	—	2.28	(12.69)	(3.84)	(17.26)	(2.26)	27.31	(10.66)	9.61	(36.16)
	Net income	—	3	(154)	408	(183)	696	140	(20)	49	(292)
	Depreciation	—	136	157	198	198	87	73	105	48	54
Per share, $
Per share, $	Revenue	—	7.44	8.28	9.19	9.82	3.49	4.44	5.25	5.83	5.49
	Earnings	—	(0.14)	(1.09)	2.07	(1.10)	4.40	1.03	(0.77)	0.45	(2.71)
	Cash flow	—	1.44	1.55	0.39	0.28	(0.65)	(0.59)	1.04	0.93	(0.19)
	Capex	—	(0.67)	(0.87)	(0.76)	(0.72)	(0.28)	(0.32)	(0.29)	(0.27)	(0.28)
	Free cash flow	—	0.78	0.68	(0.37)	(0.44)	(0.94)	(0.91)	0.75	0.65	(0.46)
	Book value	—	6.84	6.42	8.98	7.73	10.46	10.45	9.08	10.01	7.43
	Shares, m	—	186	181	176	166	159	130	112	107	108
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	4.57	0.00	3.11	17.08	0.00	0.00	0.00
	P/S	—	1.47	1.81	1.05	1.00	4.14	4.16	3.28	2.05	1.86
	P/B	—	1.60	2.34	1.07	1.27	1.38	1.77	1.90	1.18	1.07
	EV/Sales	—	2.35	2.35	1.35	1.48	3.56	4.61	2.94	1.71	1.52
	EV/FCF	—	22.53	28.71	(33.07)	(32.80)	(13.27)	(22.58)	20.47	11.89	10.57
Cash, $m
Cash, $m	Operating cash flow	—	269	279	68	46	(104)	(77)	117	100	(20)
	Capex	—	(124)	(157)	(134)	(120)	(45)	(41)	(32)	(29)	(30)
	Free cash flow	—	145	122	(66)	(74)	(149)	(118)	85	70	(50)
Balance, $m
Balance, $m	Working capital	—	(63)	(33)	61	(369)	218	161	449	253	124
	Total debt	—	1,322	937	668	915	190	370	200	205	227
	Net debt	—	1,226	806	483	778	(348)	235	(248)	(241)	(67)
	Shareholders’ equity	—	1,273	1,160	1,580	1,285	1,666	1,360	1,018	1,074	804
Returns, %
Returns, %	ROA	—	(0.79)	(4.87)	9.82	(5.70)	22.73	5.34	(4.53)	3.20	(19.93)
	ROIC	—	1.69	0.40	(5.10)	(3.02)	0.38	3.01	(2.20)	2.60	(16.52)
	ROE	—	(1.91)	(16.15)	26.55	(12.71)	47.17	9.22	(7.27)	4.70	(31.04)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2022 · fundamentals updated 1 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TDOC Teladoc Health, Inc.	$1.1B	— (loss-making)	— (loss-making)	−3.95% (below 0%: shrinking)	n/m	−27.07% (below 0%: shrinking)	68.56%	(6.11%)	Compare
HSTM HealthStream, Inc.	$1.0B	46.0×	34.4×	+12.55% (above 0%: growing)	+27.78% (above 0%: growing)	+362.71% (above 0%: growing)	65.35%	9.94%	Compare
PHR Phreesia, Inc.	$685.3M	64.4×	23.5×	+10.41% (above 0%: growing)	+200.00% (above 0%: growing)	+43.51% (above 0%: growing)	66.64%	5.88%	Compare
MDRX Veradigm Inc.	$654.5M	— (loss-making)	— (loss-making)	−9.74% (below 0%: shrinking)	n/m	−66.33% (below 0%: shrinking)	50.53%	(37.41%)
SOPH SOPHiA GENETICS SA	$620.6M	— (loss-making)	— (loss-making)	+27.22% (above 0%: growing)	n/m	+6.50% (above 0%: growing)	64.61%	(86.03%)	Compare
WEAV Weave Communications, Inc.	$594.5M	— (loss-making)	— (loss-making)	+15.52% (above 0%: growing)	n/m	+94.33% (above 0%: growing)	72.03%	(6.49%)	Compare
EVH Evolent Health, Inc	$550.6M	— (loss-making)	— (loss-making)	+46.86% (above 0%: growing)	n/m	+58.67% (above 0%: growing)	12.39%	(1.47%)	Compare
NRC National Research Corporation	$466.9M	80.6×	4.9×	+3.98% (above 0%: growing)	n/m	+101.49% (above 0%: growing)	61.67%	(9.15%)	Compare
CTEV Claritev Corporation	$404.4M	— (loss-making)	— (loss-making)	+6.59% (above 0%: growing)	n/m	+49.10% (above 0%: growing)	73.72%	9.09%	Compare
Median of peers	$607.6M	64.4×	23.5×	+11.48%	—	+53.89%	66.00%	(3.79%)

All 51 Health Information Services stocks →

Veradigm Inc. (MDRX) key facts

Veradigm Inc. (MDRX) is a Health Information Services company in the Healthcare sector.
As of October 16, 2026, MDRX traded at $5.00, a market capitalization of $654.5 million.
Return on equity was −31.0% and debt-to-equity 0.20.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is 1.65 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 1, 2026.